US Stock Price Movement: Xeris Biopharma surged on October 19 following KEVEYIS litigation and endocrine data

Bitget

News

Bitget异动解读2026/10/19 16:31

Show original

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Xeris Biopharma October 19th Surge Interpretation

Keywords: KEVEYIS litigation, endocrine data

1. On October 13th, Xeris, through its subsidiary, filed two infringement lawsuits regarding its US patents related to KEVEYIS in the federal district court of New Jersey, accusing relevant companies of infringing patents with their generic dichlorphenamide products and seeking injunctions and damages as remedies.

2. On October 15th, the company announced it will present clinical and scientific data on its commercial products and R&D pipeline at three scientific conferences, including Gvoke for severe hypoglycemia, Recorlev for Cushing's syndrome, and XP-8121 for hypothyroidism.

(Disclaimer: This content is generated by AI technology summarizing publicly available information, for reference only, and does not constitute investment advice.)

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

If the agreement is implemented, the total scale of cooperation between the two parties will reach $90 billions. The relevant negotiations involve the second building of the Monarch data center campus, which provides 460MW of computing power and adopts NVIDIA’s latest generation Vera Rubin chips. In addition, Anthropic has also obtained the priority negotiation rights for the third building in the Monarch campus plan.

华尔街见闻•2026/10/19 20:51